Pfizer
Pfizer Discontinues Phase III Trial for Sickle Cell Treatment Amid Challenges in Patient Recruitment
Pfizer, Sickle Cell Disease, Phase III Study, Inclacumab, Poor Accrual, Recruitment Challenges, THRIVE Program, ClinicalTrials.gov, Gene Therapies
Pfizer Reduces Stake in Haleon, Raising Over $2 Billion in Share Selloff
Pfizer, Haleon, Consumer Health Spinoff, Share Selloff, Stake Reduction, GSK, Debt Management, Strategic Focus